{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:53:35Z","timestamp":1794671615143,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study <jats:italic>CIRSE Registry for SIR-Spheres\u00ae Therapy (CIRT)<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and Methods<\/jats:title>\n                <jats:p>Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24\u00a0months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Totally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and\/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5\u00a0months (95% confidence interval (CI) 14.2\u201319.3) for hepatocellular carcinoma, 14.6\u00a0months (95% CI 10.9\u201317.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8\u00a0months (95% CI 8.3\u201312.9), 5.6\u00a0months for pancreatic cancer (95% CI 4.1\u20136.6), 10.6\u00a0months (95% CI 7.3\u201314.4) for breast cancer, 14.6\u00a0months (95% CI 7.3\u201321.4) for melanoma and 33.1\u00a0months (95% CI 22.1\u2013nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30\u00a0days after TARE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Level of evidence<\/jats:title>\n                <jats:p>Level 3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov NCT02305459.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00270-020-02642-y","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T22:02:23Z","timestamp":1600725743000},"page":"21-35","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)"],"prefix":"10.1007","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct02305459","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Thomas","family":"Helmberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Golfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pfammatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Maleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Munneke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Pellerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Peynircioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-2973","authenticated-orcid":false,"given":"Niels","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ignacio","family":"Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of\u00a0the CIRT Steering Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Pelage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek M.","family":"Manas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank T.","family":"Kolligs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of\u00a0the CIRT Principal Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"D\u2019Archambeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugsan","family":"Balli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadik","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Fischbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Gr\u00f6zinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Robert","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Kuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Ozgun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"2642_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016. https:\/\/doi.org\/10.1093\/annonc\/mdw235.","journal-title":"Ann Oncol."},{"key":"2642_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw324","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016. https:\/\/doi.org\/10.1093\/annonc\/mdw324.","journal-title":"Ann Oncol."},{"key":"2642_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1812-2","author":"F Giammarile","year":"2011","unstructured":"Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011. https:\/\/doi.org\/10.1007\/s00259-011-1812-2.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2642_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol."},{"key":"2642_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.001","author":"JF Dufour","year":"2012","unstructured":"Dufour JF, Greten TF, Raymond E, et al. Clinical practice guidelines EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma european organisation for research and treatment of cancer. J Hepatol. 2012. https:\/\/doi.org\/10.1016\/j.jhep.2011.12.001.","journal-title":"J Hepatol."},{"key":"2642_CR6","unstructured":"Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae) Colon Cancer, Version 4.2020. NCCN website. 15 June 2020. Accessed 24 August 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf"},{"key":"2642_CR7","unstructured":"Benson AB, D\u2019Angelica MI, Abbott DE, et al. NCCN Clinical practice guidelines in oncology (NCCN Guidelines \u00ae) Hepatobiliary Cancers, Version 5.2020. NCCN website. 4 August 2020. Accessed 24 August 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf"},{"key":"2642_CR8","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1394142","author":"B Sangro","year":"2014","unstructured":"Sangro B, Salem R. Transarterial chemoembolization and radioembolization. Semin Liver Dis. 2014. https:\/\/doi.org\/10.1055\/s-0034-1394142.","journal-title":"Semin Liver Dis."},{"key":"2642_CR9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.006","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010. https:\/\/doi.org\/10.1053\/j.gastro.2009.09.006.","journal-title":"Gastroenterology."},{"key":"2642_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26014","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013. https:\/\/doi.org\/10.1002\/hep.26014.","journal-title":"Hepatology."},{"key":"2642_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23944","author":"P Hilgard","year":"2010","unstructured":"Hilgard P, Hamami M, El Fouly A, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010. https:\/\/doi.org\/10.1002\/hep.23944.","journal-title":"Hepatology."},{"key":"2642_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24451","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R, et al. Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011. https:\/\/doi.org\/10.1002\/hep.24451.","journal-title":"Hepatology."},{"key":"2642_CR13","unstructured":"Mancini R, Carpanese L, Sciuto R, et al. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90Yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: Preliminary results on toxicity and response rates. In Vivo (Brooklyn). 2006."},{"key":"2642_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2013.11.010","author":"CT Sofocleous","year":"2014","unstructured":"Sofocleous CT, Garcia AR, Pandit-Taskar N, et al. Phase i trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014. https:\/\/doi.org\/10.1016\/j.clcc.2013.11.010.","journal-title":"Clin Colorectal Cancer."},{"key":"2642_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3182546c50","author":"SA Gulec","year":"2013","unstructured":"Gulec SA, Pennington K, Wheeler J, et al. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (Chemo-SIRT) for colorectal cancer liver metastases: An in vivo double-arm-controlled phase II trial. Am J Clin Oncol Cancer Clin Trials. 2013. https:\/\/doi.org\/10.1097\/COC.0b013e3182546c50.","journal-title":"Am J Clin Oncol Cancer Clin Trials."},{"key":"2642_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2011.12.002","author":"LK Martin","year":"2012","unstructured":"Martin LK, Cucci A, Wei L, et al. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer. 2012. https:\/\/doi.org\/10.1016\/j.clcc.2011.12.002.","journal-title":"Clin Colorectal Cancer."},{"key":"2642_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.5643","author":"A Hendlisz","year":"2010","unstructured":"Hendlisz A, Van Den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010. https:\/\/doi.org\/10.1200\/JCO.2010.28.5643.","journal-title":"J Clin Oncol."},{"key":"2642_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30683-6","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017. https:\/\/doi.org\/10.1016\/S1470-2045(17)30683-6.","journal-title":"Lancet Oncol."},{"key":"2642_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30457-6","author":"HS Wasan","year":"2017","unstructured":"Wasan HS, Gibbs P, Sharma N, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017. https:\/\/doi.org\/10.1016\/S1470-2045(17)30457-6.","journal-title":"Lancet Oncol."},{"key":"2642_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.35.15_suppl.3507","author":"RA Sharma","year":"2018","unstructured":"Sharma RA, Wasan HS, Van Hazel GA, et al. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.3507.","journal-title":"J Clin Oncol."},{"key":"2642_CR21","doi-asserted-by":"publisher","DOI":"10.2196\/11545","author":"N Chauhan","year":"2019","unstructured":"Chauhan N, Mulcahy MF, Salem R, et al. Therasphere yttrium-90 glass microspheres combined with chemotherapy versus chemotherapy alone in second-line treatment of patients with metastatic colorectal carcinoma of the liver: Protocol for the EPOCH phase 3 randomized clinical trial. J Med Internet Res. 2019. https:\/\/doi.org\/10.2196\/11545.","journal-title":"J Med Internet Res."},{"key":"2642_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0892","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2017.76.0892.","journal-title":"J Clin Oncol."},{"key":"2642_CR23","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4164-x","author":"A Saxena","year":"2015","unstructured":"Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L. Is Yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol. 2015. https:\/\/doi.org\/10.1245\/s10434-014-4164-x.","journal-title":"Ann Surg Oncol."},{"key":"2642_CR24","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2014.109","author":"AS Kennedy","year":"2015","unstructured":"Kennedy AS, Ball D, Cohen SJ, et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for 90Y resin microspheres. J Gastrointest Oncol. 2015. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2014.109.","journal-title":"J Gastrointest Oncol."},{"key":"2642_CR25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11644","author":"C Rognoni","year":"2016","unstructured":"Rognoni C, Ciani O, Sommariva S, et al. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: Systematic review and meta-analyses. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.11644.","journal-title":"Oncotarget."},{"key":"2642_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04427-z","author":"H Levillain","year":"2019","unstructured":"Levillain H, Duran Derijckere I, Ameye L, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019. https:\/\/doi.org\/10.1007\/s00259-019-04427-z.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2642_CR27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08486-7","author":"D Riby","year":"2020","unstructured":"Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08486-7.","journal-title":"Ann Surg Oncol."},{"key":"2642_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13382","author":"A Cucchetti","year":"2017","unstructured":"Cucchetti A, Cappelli A, Mosconi C, et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: a meta-regression study. Liver Int. 2017. https:\/\/doi.org\/10.1111\/liv.13382.","journal-title":"Liver Int."},{"key":"2642_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3968-5","author":"B Sangro","year":"2018","unstructured":"Sangro B, Maini CL, Ettorre GM, et al. Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Eur J Nucl Med Mol Imaging. 2018. https:\/\/doi.org\/10.1007\/s00259-018-3968-5.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2642_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-020-02569-4","author":"I Bargellini","year":"2020","unstructured":"Bargellini I, Mosconi C, Pizzi G, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol. 2020. https:\/\/doi.org\/10.1007\/s00270-020-02569-4.","journal-title":"Cardiovasc Intervent Radiol."},{"key":"2642_CR31","doi-asserted-by":"publisher","unstructured":"Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. HepatoBiliary Surg Nutr. 2018. https:\/\/doi.org\/10.21037\/hbsn.2018.10.06","DOI":"10.21037\/hbsn.2018.10.06"},{"issue":"1","key":"2642_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clon.2018.09.002","volume":"31","author":"J White","year":"2019","unstructured":"White J, Carolan-Rees G, Dale M, et al. Analysis of a national programme for selective internal radiation therapy for colorectal cancer liver metastases. Clin Oncol. 2019;31(1):58\u201366. https:\/\/doi.org\/10.1016\/j.clon.2018.09.002.","journal-title":"Clin Oncol."},{"issue":"8","key":"2642_CR33","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jvir.2019.03.018","volume":"30","author":"J White","year":"2019","unstructured":"White J, Carolan-Rees G, Dale M, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective. Observational Study. J Vasc Interv Radiol. 2019;30(8):1185\u201392. https:\/\/doi.org\/10.1016\/j.jvir.2019.03.018.","journal-title":"Observational Study. J Vasc Interv Radiol."},{"key":"2642_CR34","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i27.8271","author":"A Kuei","year":"2015","unstructured":"Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World J Gastroenterol. 2015. https:\/\/doi.org\/10.3748\/wjg.v21.i27.8271.","journal-title":"World J Gastroenterol."},{"key":"2642_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3264-6","author":"CE Barbier","year":"2016","unstructured":"Barbier CE, Garske-Rom\u00e1n U, Sandstr\u00f6m M, Nyman R, Granberg D. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2016. https:\/\/doi.org\/10.1007\/s00259-015-3264-6.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"2642_CR36","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1159\/000441689","volume":"31","author":"G Puippe","year":"2015","unstructured":"Puippe G, Pfammatter T, Schaefer N. Arterial therapies of non-colorectal liver metastases. Visz Gastrointest Med Surg. 2015;31(6):414\u201322. https:\/\/doi.org\/10.1159\/000441689.","journal-title":"Visz Gastrointest Med Surg."},{"key":"2642_CR37","doi-asserted-by":"publisher","DOI":"10.2196\/16296","author":"T Helmberger","year":"2020","unstructured":"Helmberger T, Arnold D, Bilbao JI, et al. Clinical application of radioembolization in hepatic malignancies: Protocol for a prospective multicenter observational study. J Med Internet Res. 2020. https:\/\/doi.org\/10.2196\/16296.","journal-title":"J Med Internet Res."},{"key":"2642_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.08.004","author":"I Kurilova","year":"2019","unstructured":"Kurilova I, Beets-Tan RGH, Flynn J, et al. Factors affecting oncologic outcomes of 90Y radioembolization of heavily pre-treated patients with colon cancer liver metastases. Clin Colorectal Cancer. 2019. https:\/\/doi.org\/10.1016\/j.clcc.2018.08.004.","journal-title":"Clin Colorectal Cancer."},{"key":"2642_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2549-x","author":"R Damm","year":"2016","unstructured":"Damm R, Seidensticker R, Ulrich G, et al. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer. 2016. https:\/\/doi.org\/10.1186\/s12885-016-2549-x.","journal-title":"BMC Cancer."},{"key":"2642_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2015.06.003","author":"CT Sofocleous","year":"2015","unstructured":"Sofocleous CT, Violari EG, Sotirchos VS, et al. Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin Colorectal Cancer. 2015. https:\/\/doi.org\/10.1016\/j.clcc.2015.06.003.","journal-title":"Clin Colorectal Cancer."},{"key":"2642_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072302","author":"M Barat","year":"2020","unstructured":"Barat M, Cottereau A-S, Kedra A, et al. The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9072302.","journal-title":"J Clin Med."},{"key":"2642_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2018.01.012","author":"Z Jia","year":"2018","unstructured":"Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol. 2018. https:\/\/doi.org\/10.1016\/j.ejrad.2018.01.012.","journal-title":"Eur J Radiol."},{"key":"2642_CR43","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.10.05","author":"DA Zuckerman","year":"2019","unstructured":"Zuckerman DA, Kennard RF, Roy A, Parikh PJ, Weiner AA. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors\u2014a single-institution experience. J Gastrointest Oncol. 2019. https:\/\/doi.org\/10.21037\/jgo.2018.10.05.","journal-title":"J Gastrointest Oncol."},{"key":"2642_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091341","author":"R Bale","year":"2019","unstructured":"Bale R, Putzer D, Schullian P. Local treatment of breast cancer liver metastasis. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11091341.","journal-title":"Cancers (Basel)."},{"key":"2642_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2014.07.007","author":"AC Gordon","year":"2014","unstructured":"Gordon AC, Gradishar WJ, Kaklamani VG, et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol. 2014. https:\/\/doi.org\/10.1016\/j.jvir.2014.07.007.","journal-title":"J Vasc Interv Radiol."},{"key":"2642_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.01.009","author":"TF Jakobs","year":"2008","unstructured":"Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008. https:\/\/doi.org\/10.1016\/j.jvir.2008.01.009.","journal-title":"J Vasc Interv Radiol."},{"key":"2642_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2019.11.002","author":"A Rowcroft","year":"2020","unstructured":"Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB. 2020. https:\/\/doi.org\/10.1016\/j.hpb.2019.11.002.","journal-title":"HPB."},{"key":"2642_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1822-8","author":"P Gibbs","year":"2015","unstructured":"Gibbs P, Do C, Lipton L, et al. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer. 2015. https:\/\/doi.org\/10.1186\/s12885-015-1822-8.","journal-title":"BMC Cancer."},{"key":"2642_CR49","doi-asserted-by":"publisher","DOI":"10.1159\/000355821","author":"M Michl","year":"2014","unstructured":"Michl M, Haug AR, Jakobs TF, et al. Radioembolization with yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: Efficacy, safety and prognostic factors. Oncol. 2014. https:\/\/doi.org\/10.1159\/000355821.","journal-title":"Oncol."},{"key":"2642_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1465587","author":"S Tulokas","year":"2018","unstructured":"Tulokas S, M\u00e4enp\u00e4\u00e4 H, Peltola E, et al. Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience. Acta Oncol (Madr). 2018. https:\/\/doi.org\/10.1080\/0284186X.2018.1465587.","journal-title":"Acta Oncol (Madr)."},{"key":"2642_CR51","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3702","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702.","journal-title":"JAMA Oncol."},{"key":"2642_CR52","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v12.i2.228","author":"M Feretis","year":"2020","unstructured":"Feretis M, Solodkyy A. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: a systematic review. World J Gastrointest Oncol. 2020. https:\/\/doi.org\/10.4251\/wjgo.v12.i2.228.","journal-title":"World J Gastrointest Oncol."},{"key":"2642_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000109","author":"M Xing","year":"2017","unstructured":"Xing M, Prajapati HJ, Dhanasekaran R, et al. Selective internal yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy: Safety and efficacy cohort study. Am J Clin Oncol Cancer Clin Trials. 2017. https:\/\/doi.org\/10.1097\/COC.0000000000000109.","journal-title":"Am J Clin Oncol Cancer Clin Trials."},{"key":"2642_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2014.09.007","author":"DP Al-Adra","year":"2015","unstructured":"Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015. https:\/\/doi.org\/10.1016\/j.ejso.2014.09.007.","journal-title":"Eur J Surg Oncol."},{"key":"2642_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23781","author":"LM Boehm","year":"2015","unstructured":"Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015. https:\/\/doi.org\/10.1002\/jso.23781.","journal-title":"J Surg Oncol."},{"key":"2642_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(18)30424-0","author":"J Ricke","year":"2018","unstructured":"Ricke J, Sangro B, Amthauer H, et al. The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the soramic trial palliative cohort. J Hepatol. 2018. https:\/\/doi.org\/10.1016\/s0168-8278(18)30424-0.","journal-title":"J Hepatol."},{"key":"2642_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2020.1777856","author":"MA Abdallah","year":"2020","unstructured":"Abdallah MA, Wongjarupong N, Hassan MA, et al. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Rev Gastroenterol Hepatol. 2020. https:\/\/doi.org\/10.1080\/17474124.2020.1777856.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"2642_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29691","author":"R Salem","year":"2018","unstructured":"Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1000-patient 15-year experience. Hepatology. 2018. https:\/\/doi.org\/10.1002\/hep.29691.","journal-title":"Hepatology."},{"key":"2642_CR59","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.199752","author":"N Abouchaleh","year":"2018","unstructured":"Abouchaleh N, Gabr A, Ali R, et al. 90 Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: Long-term outcomes in a 185-patient cohort. J Nucl Med. 2018. https:\/\/doi.org\/10.2967\/jnumed.117.199752.","journal-title":"J Nucl Med."},{"key":"2642_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-017-1871-2","author":"P Reimer","year":"2018","unstructured":"Reimer P, Virarkar MK, Binnenhei M, Justinger M, Sch\u00f6n MR, Tatsch K. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-na\u00efve patients. Cardiovasc Intervent Radiol. 2018. https:\/\/doi.org\/10.1007\/s00270-017-1871-2.","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"1","key":"2642_CR61","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/jcm9010056","volume":"9","author":"M K\u00f6hler","year":"2019","unstructured":"K\u00f6hler M, Harders F, Loh\u00f6fer F, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9(1):56. https:\/\/doi.org\/10.3390\/jcm9010056.","journal-title":"J Clin Med."},{"key":"2642_CR62","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.166082","author":"R Hickey","year":"2016","unstructured":"Hickey R, Lewandowski RJ, Prudhomme T, et al. 90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med. 2016. https:\/\/doi.org\/10.2967\/jnumed.115.166082.","journal-title":"J Nucl Med."},{"key":"2642_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21980","author":"LM Kulik","year":"2008","unstructured":"Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008. https:\/\/doi.org\/10.1002\/hep.21980.","journal-title":"Hepatology."},{"key":"2642_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.07.012","author":"B Sangro","year":"2012","unstructured":"Sangro B, I\u00f1arrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012. https:\/\/doi.org\/10.1016\/j.jhep.2011.07.012.","journal-title":"J Hepatol."},{"key":"2642_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2015.05.032","author":"SJ Lahti","year":"2015","unstructured":"Lahti SJ, Xing M, Zhang D, Lee JJ, Magnetta MJ, Kim HS. KRAS status as an independent prognostic factor for survival after yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastases. J Vasc Interv Radiol. 2015. https:\/\/doi.org\/10.1016\/j.jvir.2015.05.032.","journal-title":"J Vasc Interv Radiol."},{"key":"2642_CR66","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15278","author":"E Ziv","year":"2017","unstructured":"Ziv E, Bergen M, Yarmohammadi H, et al. PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget. 2017. https:\/\/doi.org\/10.18632\/oncotarget.15278.","journal-title":"Oncotarget."},{"key":"2642_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2015.12.031","author":"A van den Hoven","year":"2016","unstructured":"van den Hoven A, Rosenbaum C, Elias S, et al. Insights into the dose-response relationship of hepatic radioembolization with resin yttrium-90 microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Vasc Interv Radiol. 2016. https:\/\/doi.org\/10.1016\/j.jvir.2015.12.031.","journal-title":"J Vasc Interv Radiol."},{"key":"2642_CR68","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020191606","author":"A-L Hermann","year":"2020","unstructured":"Hermann A-L, Dieudonn\u00e9 A, Ronot M, et al. Relationship of tumor radiation\u2013absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90 Y in the SARAH study. Radiology. 2020. https:\/\/doi.org\/10.1148\/radiol.2020191606.","journal-title":"Radiology."},{"key":"2642_CR69","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020202354","author":"CT Sofocleous","year":"2020","unstructured":"Sofocleous CT, Vasiniotis Kamarinos N. Tumor-absolbed dose: the missing link in radioembolization. Radiology. 2020. https:\/\/doi.org\/10.1148\/radiol.2020202354.","journal-title":"Radiology."},{"key":"2642_CR70","unstructured":"Adam A, De Ba\u00e8re T, Bilbao JI, et al. Standards of quality assurance in interventional oncology, First Edition. CIRSE\u2013Cardiovascular and Interventional Radiological Society of Europe. 2018. ISBN 978-3-9502501-5-2"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-020-02642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-020-02642-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-020-02642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T23:33:04Z","timestamp":1632180784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-020-02642-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2642"],"URL":"https:\/\/doi.org\/10.1007\/s00270-020-02642-y","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"JB and GM received speaker fees and proctor fees from SIRTEX Medical, BP received proctor fees from SIRTEX Medical, MP reported grants from Bayer and SIRTEX during the course of the study, OP is shareholder of GOGITh-SAS, NdJ is an employee of CIRSE, BS received grants, personal fees and non-financial support from SIRTEX Medical and BMS, grants and personal fees from Onxeo, personal fees and non-financial support from Astra Zeneca, Bayer, Ipsen, and BTG, and personal fees from Lilly, Eisai and Roche. DA is on the advisory board of Terumo, Boston Scientific, SIRTEX Medical Europe and Biocompatibles. RC, RG, TH, NS, TP and GM declared no conflict of interest. All authors report no conflict of interest directly related to the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study, consent for publication is not required. However, consent for publication was obtained for every individual person\u2019s data included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}